Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR) closed the sale of an additional 648,373 Class A ordinary shares on September 29, 2026. This transaction completed the full exercise of the underwriter’s over-allotment option in connection with the company’s public offering.

The shares were sold at a price of $1.15 per share, generating approximately $745,629 in gross proceeds before underwriting discounts and expenses. With this closing, the company has raised aggregate gross proceeds of approximately $5,716,491.

Offering details and proceeds

The over-allotment exercise adds to the previously announced public offering gross proceeds of approximately $4,970,862. The total capital raised supports the company's strategic initiatives in the biomedical sector.

Use of funds and strategic focus

Cuprina intends to deploy the net proceeds from the offering across several key areas. These include expansion into new businesses, research and development activities to broaden product offerings, and growth into new markets. Additional allocations are designated for building brand awareness, investing in equipment and infrastructure, and general working capital purposes.

The company operates in the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors. It is a Singapore-based biomedical and biotechnology firm dedicated to developing innovative products using materials derived from natural sources.

Regulatory and advisory context

The offering was conducted pursuant to the company’s Registration Statement on Form F-1 (File No: 333-297299), which was declared effective by the U.S. Securities and Exchange Commission (SEC) on September 15, 2026. R. F. Lafferty & Co., Inc. served as the sole book-running manager for the transaction.

Legal counsel for the company included Loeb & Loeb LLP for U.S. matters, Lee & Lee for Singapore matters, and Harney Westwood & Riegels Singapore LLP for Cayman Islands matters. Ellenoff Grossman & Schole LLP acted as U.S. legal counsel to the underwriter.

Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR) announced the closing of its public offering of 4,322,489 Class A Ordinary Shares. The Singapore-based biomedical company raised gross proceeds of $4.97 million from the sale at $1.15 per share.

The transaction closes on September 17, 2026. R. F. Lafferty & Co., Inc. acted as the sole book-running manager for the offering.

Offering Details

The company granted the underwriter a 45-day option to purchase up to an additional 648,373 shares, representing 15% of the initial shares sold. If fully exercised, this over-allotment would increase total gross proceeds to approximately $5.72 million, before deducting underwriting discounts and estimated expenses.

Use of Proceeds

Cuprina intends to use the net proceeds for expansion into new businesses, research and development activities to expand product offerings, and growth into new markets. Additional uses include building brand awareness, investing in equipment and infrastructure, and general corporate purposes.

Management Commentary

David Quek, Chief Executive Officer of Cuprina, stated that the offering follows the U.S. FDA 510(k) clearance for MEDIFLY Maggots™ in June. He noted that the company plans to build out new business collaborations, advance its wound care pipeline, and expand into new markets.

"Chronic wounds remain the core of our business," Quek said. "We believe demand for effective wound care will keep growing as populations age and rates of diabetes, obesity, cardiovascular disease and peripheral vascular disease rise."

Regulatory and Legal Framework

The offering was conducted pursuant to Registration Statement on Form F-1 (File No: 333-297299), which was declared effective by the U.S. Securities and Exchange Commission on September 15, 2026.

Legal counsel for the transaction included:

• Loeb & Loeb LLP (U.S.)
• Lee & Lee (Singapore)
• Harney Westwood & Riegels Singapore LLP (Cayman Islands)
• Ellenoff Grossman & Schole LLP (U.S. counsel to R. F. Lafferty)

About Cuprina Holdings

Cuprina develops and markets products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals. The company utilizes materials derived from natural sources to develop wound care products that meet international standards.